2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2783

Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous
Abstract Number: 2533

Hydroxychloroquine Increases Low C3 in SLE
Abstract Number: 2517

Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS
Abstract Number: 2573

Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels
Abstract Number: 322

Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Abstract Number: 896

Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1891

Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis
Abstract Number: 226

Hypersensitivity Beyond Pain: Hyperacusis and Hyperalgesia of Patients with Fibromyalgia
Abstract Number: 2862

Hypoxia Resistant Pathogenic B Cells Accumulate in the RA Synovial Tissue in a CXCR3 Dependent Manner
Abstract Number: L19

Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Abstract Number: 774

Identical T Cell Clones Identified over Time in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Abstract Number: 1233

Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Abstract Number: 1929

Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women
Abstract Number: 1090

Identification of a Distinct Intestinal Behçet’s Disease Cluster in Japan: A Nationwide Retrospective Observational Study
Abstract Number: 2487

Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].